Evidence map›Paper›PMID 28746311›Full record

ArticleNature2017

Prolonged Mek1/2 suppression impairs the developmental potential of embryonic stem cells.

Jiho Choi, Aaron J Huebner, Kendell Clement, Ryan M Walsh, Andrej Savol, Kaixuan Lin, Hongcang Gu, Bruno Di Stefano, Justin Brumbaugh, Sang-Yong Kim and 13 more

Open access · bronzeAbstract read
In one paragraph

Article in Nature, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 173 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
173citing papers in PubMed, 1 pooled it
13.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

173 citing papers in PubMed, 1 synthesis or guideline pooled it, 290 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. The making of cells and organs in xenogeneic animal bioreactor.Signal transduction and targeted therapy · 2026
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

113 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors at 7 institutions in 3 countries.

Jiho ChoiMassachusetts General Hospital Department of Molecular Biology, Boston, Massachusetts 02114, USA.
Aaron J HuebnerMassachusetts General Hospital Department of Molecular Biology, Boston, Massachusetts 02114, USA.
Kendell ClementDepartment of Stem Cell and Regenerative Biology, Harvard University, Cambridge, Massachusetts 02138, USA.
Ryan M WalshMassachusetts General Hospital Department of Molecular Biology, Boston, Massachusetts 02114, USA.
Andrej SavolMassachusetts General Hospital Department of Molecular Biology, Boston, Massachusetts 02114, USA.
Kaixuan LinDepartment of Genetics, Yale University School of Medicine, 10 Amistad Street, New Haven, Connecticut 06519, USA.
Hongcang GuBroad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA.
Bruno Di StefanoMassachusetts General Hospital Department of Molecular Biology, Boston, Massachusetts 02114, USA.
Justin BrumbaughMassachusetts General Hospital Department of Molecular Biology, Boston, Massachusetts 02114, USA.
Sang-Yong KimNew York University Langone Medical Center, New York 10016, USA.
Jafar SharifCenter for Integrative Medical Sciences, RIKEN National Research and Development Agency, 1-7-22 Suehiuro-cho, Tsurumi-ku, Yokohama-shi, Kanagawa-ken 230-0045, Japan.
Christopher M RoseDepartment of Cell Biology, Harvard Medical School, 240 Longwood Avenue, Boston, Massachusetts 02115, USA.
Arman MohammadBroad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA.
Junko OdajimaMassachusetts General Hospital Cancer Center and Center for Regenerative Medicine, Boston, Massachusetts 02114, USA.
Jean CharronCentre de recherche sur le cancer de l'Université Laval, CRCHU de Québec, L'Hôtel-Dieu de Québec, 9, rue McMahon, Quebec G1R 2J6, Canada.
Toshi ShiodaMassachusetts General Hospital Cancer Center and Center for Regenerative Medicine, Boston, Massachusetts 02114, USA.
Andreas GnirkeBroad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA.
Steven GygiDepartment of Cell Biology, Harvard Medical School, 240 Longwood Avenue, Boston, Massachusetts 02115, USA.
Haruhiko KosekiCenter for Integrative Medical Sciences, RIKEN National Research and Development Agency, 1-7-22 Suehiuro-cho, Tsurumi-ku, Yokohama-shi, Kanagawa-ken 230-0045, Japan.
Ruslan I SadreyevMassachusetts General Hospital Department of Molecular Biology, Boston, Massachusetts 02114, USA.
Andrew XiaoDepartment of Genetics, Yale University School of Medicine, 10 Amistad Street, New Haven, Connecticut 06519, USA.
Alexander MeissnerDepartment of Stem Cell and Regenerative Biology, Harvard University, Cambridge, Massachusetts 02138, USA.
Konrad HochedlingerMassachusetts General Hospital Department of Molecular Biology, Boston, Massachusetts 02114, USA.
Massachusetts General Hospital · USBroad Institute · USHarvard University · USRIKEN Center for Integrative Medical Sciences · JPYale University · USNYU Langone Health · USUniversité Laval · CA

Funding

Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI ALAN KEITH MEEKER · 1985 to 2026
$208.6M
ROLE OF DIETARY CONSTITUENTS ON GENE EXPRESSION IN INTESTINAL EPITHELIUMP30DK040561 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI Takara Leah Stanley · 1994 to 2026
$31.6M
Center for Cell CircuitsP50HG006193 · NHGRI · BROAD INSTITUTE, INC. · PI REGEV, AVIV · 2011 to 2015
$15.6M
Transcription Factor Induced ReprogrammingR01HD058013 · NICHD · MASSACHUSETTS GENERAL HOSPITAL · PI HOCHEDLINGER, KONRAD · 2010 to 2019
$4.4M
Investigate Novel Epigenetic Silencing Mechanisms in Mouse ESCsR01GM114205 · NIGMS · YALE UNIVERSITY · PI XIAO, ZHUO ANDREW · 2015 to 2019
$2.1M
Roles of Nuclear Receptors in Generation of Heritable Epimutations in Germ CellsR21ES024861 · NIEHS · MASSACHUSETTS GENERAL HOSPITAL · PI SHIODA, TOSHIHIRO · 2015 to 2016
$471k
NCI NIH HHS P30 CA006973NHGRI NIH HHS P50 HG006193NICHD NIH HHS R01 HD058013NIDDK NIH HHS P30 DK040561NIEHS NIH HHS R21 ES024861NIGMS NIH HHS R01 GM114205NIH HHS 1P50HG006193
6 · The paper itself

Abstract

Concomitant activation of the Wnt pathway and suppression of Mapk signalling by two small molecule inhibitors (2i) in the presence of leukaemia inhibitory factor (LIF) (hereafter termed 2i/L) induces a naive state in mouse embryonic stem (ES) cells that resembles the inner cell mass (ICM) of the pre-implantation embryo. Since the ICM exists only transiently in vivo, it remains unclear how sustained propagation of naive ES cells in vitro affects their stability and functionality. Here we show that prolonged culture of male mouse ES cells in 2i/L results in irreversible epigenetic and genomic changes that impair their developmental potential. Furthermore, we find that female ES cells cultured in conventional serum plus LIF medium phenocopy male ES cells cultured in 2i/L. Mechanistically, we demonstrate that the inhibition of Mek1/2 is predominantly responsible for these effects, in part through the downregulation of DNA methyltransferases and their cofactors. Finally, we show that replacement of the Mek1/2 inhibitor with a Src inhibitor preserves the epigenetic and genomic integrity as well as the developmental potential of ES cells. Taken together, our data suggest that, although short-term suppression of Mek1/2 in ES cells helps to maintain an ICM-like epigenetic state, prolonged suppression results in irreversible changes that compromise their developmental potential.

Indexed as

AnimalsBlastocystChromosomal InstabilityDNA MethylationEmbryonic Stem CellsFemaleGenomic ImprintingKaryotypingMaleMAP Kinase Kinase 1MAP Kinase Kinase 2MiceMAP Kinase Kinase 1MAP Kinase Kinase 2

Identifiers

PMID28746311
PMCPMC5905676
OpenAlexW2738015524

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.